8-May-2024
TipRanks (Wed, 8-May 12:37 AM ET)
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
TipRanks (Tue, 7-May 11:58 PM ET)
TipRanks (Tue, 7-May 11:35 AM ET)
NanoViricides, TC BioPharm, Holdco Nuvo among healthcare movers
Seeking Alpha News (Tue, 7-May 10:01 AM ET)
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
Business Wire (Tue, 7-May 7:00 AM ET)
Analysts’ Top Healthcare Picks: OrthoPediatrics (KIDS), Enanta Pharmaceuticals (ENTA)
TipRanks (Tue, 7-May 1:01 AM ET)
TipRanks (Tue, 7-May 12:51 AM ET)
Enanta Pharma GAAP EPS of -$1.47 misses by $0.17, revenue of $17.05M beats by $0.84M
Seeking Alpha News (Mon, 6-May 4:04 PM ET)
Business Wire (Mon, 6-May 4:01 PM ET)
Enanta Pharma Q2 2024 Earnings Preview
Seeking Alpha News (Sun, 5-May 5:35 PM ET)
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Enanta Pharmaceuticals trades on the NASDAQ stock market under the symbol ENTA.
As of May 8, 2024, ENTA stock price declined to $12.76 with 159,868 million shares trading.
ENTA has a beta of 1.49, meaning it tends to be more sensitive to market movements. ENTA has a correlation of 0.06 to the broad based SPY ETF.
ENTA has a market cap of $269.95 million. This is considered a Small Cap stock.
Last quarter Enanta Pharmaceuticals reported $17 million in Revenue and -$1.47 earnings per share. This beat revenue expectation by $534,000 and missed earnings estimates by -$.14.
In the last 3 years, ENTA stock traded as high as $102.00 and as low as $8.08.
The top ETF exchange traded funds that ENTA belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ENTA has underperformed the market in the last year with a price return of -64.6% while the SPY ETF gained +27.0%. ENTA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +4.1% and -3.0%, respectively, while the SPY returned +4.2% and +2.3%, respectively.
ENTA support price is $12.57 and resistance is $13.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTA stock will trade within this expected range on the day.